uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
The impact of glucocorticoid replacement regimens on metabolic outcome and comorbidity in hypopituitary patients
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Pharmacy, Department of Pharmacy.
Show others and affiliations
2006 (English)In: Journal of Clinical Endocrinology and Metabolism, ISSN 0021-972X, E-ISSN 1945-7197, Vol. 91, no 10, 3954-3961 p.Article in journal (Refereed) Published
Abstract [en]

Background: Hypopituitary patients with untreated GH deficiency and patients on inappropriately high doses of glucocorticoid ( GC) share certain clinical features.

Objective: The aim of the study was to examine the influence of GC substitution on clinical characteristics in hypopituitary patients before and after GH replacement therapy.

Method: A total of 2424 hypopituitary patients within the KIMS ( Pfizer International Metabolic Database) were grouped according to ACTH status. Comparisons were performed between subjects on hydrocortisone (HC) (n = 1186), cortisone acetate (CA) (n = 487), and prednisolone/dexamethasone (n = 52), and ACTH-sufficient patients (AS) (n = 717) before and after 1 yr of GH treatment in terms of body mass index, waist and hip circumference, blood pressure, glucose, glycosylated hemoglobin (HbA1c), serum lipids, IGF-I, and comorbidity. Hydrocortisone equivalent (HCeq) doses were calculated, and measurements were adjusted for sex and age.

Results: At baseline, the HC group had increased total cholesterol, triglycerides, waist circumference, and HbA1c, and the prednisolone/ dexamethasone group had increased waist/hip ratio as compared with AS. After HCeq dose adjustment, the HC group retained higher HbA1c than the CA group. GC-treated patients showed a dose-related increase in serum IGF-I, body mass index, triglycerides, low-density lipoprotein cholesterol and total cholesterol levels. Subjects with HCeq doses less than 20 mg/d (n = 328) at baseline did not differ from AS in metabolic endpoints. The 1-yr metabolic response to GH was similar in all GC groups and dose categories. All new cases of diabetes (n = 12), stroke (n = 8), and myocardial infarction (n = 3) during GH treatment occurred in GC-treated subjects.

Conclusion: HCeq doses of at least 20 mg/d in adults with hypopituitarism are associated with an unfavorable metabolic profile. CA replacement may have metabolic advantages compared with other GCs.

Place, publisher, year, edition, pages
2006. Vol. 91, no 10, 3954-3961 p.
National Category
Medical and Health Sciences
URN: urn:nbn:se:uu:diva-22160DOI: 10.1210/jc.2006-0524ISI: 000241100900040PubMedID: 16895963OAI: oai:DiVA.org:uu-22160DiVA: diva2:49933
Available from: 2007-01-12 Created: 2007-01-12 Last updated: 2011-05-31Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed
By organisation
Department of Pharmacy
In the same journal
Journal of Clinical Endocrinology and Metabolism
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 164 hits
ReferencesLink to record
Permanent link

Direct link